Title: Preclinical and clinical pharmacology of TPA023B, a GABAA receptor a2/a3 subtype-selective partial agonis
Authors: Atack, John ×
Hallett, David J
Tye, Spencer
Wafford, Keith A
Ryan, Christine
Sanabria-Bohórquez, Sandra
Eng, Wei-Si
Gibson, Raymond E
Burns, H Donald
Dawson, Gerard R
Carling, Robert W
Street, Leslie J
Pike, Andy
De Lepeleire, Inge
Van Laere, Koen
Bormans, Guy
de Hoon, Jan
Van Hecken, Anne
McKernan, Ruth M
Murphy, M Gail
Hargreaves, Richard J #
Issue Date: Mar-2011
Publisher: Oxford University Press
Series Title: Journal of Psychopharmacology vol:25 issue:3 pages:329-344
Abstract: In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABAA receptor occupancy ( approximately 10%). Since it was not clear whether this sedation was mediated via the alpha2/alpha3 or alpha1 GABAA subtype(s), we characterized the properties of TPA023B, a high-affinity imidazotriazine which, like MRK-409, has partial agonist efficacy at the alpha2 and alpha3 subtype but is an antagonist at the alpha1 subtype, at which MRK-409 has weak partial agonism. TPA023B gave dose- and time-dependent occupancy of rat brain GABAA receptors as measured using an in vivo [(3)H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL, the latter of which was similar to that observed in mice (25 ng/mL) and comparable to values obtained in baboon and man using [(11)C]flumazenil PET (10 and 5.8 ng/mL, respectively). TPA023B was anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet had no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. In man, TPA023B was well tolerated at a dose (1.5 mg) that produced occupancy of >50%, suggesting that the sedation previously seen with MRK-409 is due to the partial agonist efficacy of that compound at the alpha1 subtype, and highlighting the importance of antagonist efficacy at this particular GABAA receptor population for avoiding sedation in man.
ISSN: 0269-8811
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Radiopharmaceutical Research
Nuclear Medicine & Molecular Imaging
Clinical Pharmacology Centre (-)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Preclinical and clinical pharmacology of TPA023B.pdf Published 464KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science